Product Overview
Retatrutide – Research‑Grade Multi‑Agonist Peptide for Metabolic and Energy‑Balance Pathway Investigation
Synonyms: LY3437943; Triple Agonist Peptide (GIP/GLP‑1/Glucagon analogue)
CAS Number: Not publicly assigned (research‑stage investigational peptide)
Sequence: Proprietary sequence (Eli Lilly investigational multi‑agonist peptide)
Molecular Weight: Not publicly standardised (varies by research supplier; typically >4 kDa)
Form: Lyophilised powder
Purity: ≥98% (HPLC)
Use: For laboratory research only. Not for human or veterinary use.
Overview
Retatrutide is an investigational multi‑agonist peptide designed to activate receptors for glucose‑dependent insulinotropic polypeptide (GIP), glucagon‑like peptide‑1 (GLP‑1), and glucagon.
It is widely used in research exploring metabolic regulation, energy expenditure, and endocrine signalling in controlled laboratory models.
Its receptor‑targeted design makes it suitable for in vitro and non‑human in vivo studies examining appetite regulation, glucose homeostasis, and lipid‑metabolism pathways.
Mechanistic Insights
Preclinical research has examined Retatrutide in relation to several metabolic and endocrine processes:
• GIP Receptor Activation – Studied for its involvement in insulinotropic signalling and metabolic regulation.
• GLP‑1 Receptor Modulation – Investigated for effects on appetite‑related pathways and glucose handling in non‑human models.
• Glucagon Receptor Activity – Explored for its potential influence on energy expenditure and lipid turnover.
• Multi‑Agonist Synergy – Evaluated for combined receptor‑pathway interactions relevant to metabolic homeostasis.
These findings are based on published scientific literature and do not imply any therapeutic or physiological effects in humans.
Research Context
Retatrutide is utilised exclusively within controlled laboratory environments for:
• Studies involving metabolic regulation and energy‑balance pathways
• Investigations into multi‑agonist receptor signalling
• Research on glucose homeostasis, lipid metabolism, and endocrine feedback loops
• Comparative studies with GLP‑1, GIP, glucagon analogues, or dual‑agonist peptides
This material is not intended for therapeutic, diagnostic, or clinical use.
Packaging & Storage
• Supplied as a sterile‑filtered, lyophilised peptide
• Store at –20°C, protected from light and moisture
• Reconstitute under sterile laboratory conditions using bacteriostatic water or a suitable research‑grade diluent
• Store reconstituted solutions at 2–8°C and use according to institutional guidelines
Additional solubility and technical documentation are available to qualified research institutions upon request.
Compliance Notice
This product is intended solely for laboratory research purposes.
It is not approved for human or veterinary administration and must not be incorporated into food, cosmetics, pharmaceuticals, or any product intended for biological exposure.
All information provided is for scientific and educational reference only. Researchers are responsible for ensuring compliance with all applicable regulations, institutional policies, and safety standards.
